Chiba University Hospital Clinical Research Center Selects Medidata Solutions

Chiba University Hospital Clinical Research Center Selects Medidata Solutions

Leading Japanese Clinical Research Institution Leverages Medidata Rave to Increase Efficiency and Expand Global Footprint

NEW YORK & TOKYO--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that the Chiba University Hospital Clinical Research Center (CCRC), one of Japan's leading clinical research institutions, has chosen Medidata Rave® as its electronic data capture (EDC) and clinical data management (CDM) solution. Designated as one of the top 10 core research centers in Japan by the Ministry of Health, Labor and Welfare (MHLW), the CCRC will start using Rave this year for investigator-initiated clinical trials.

"We look forward to benefitting from Medidata Rave's configurable and user-friendly EDC/CDM system"

Looking to replace its existing EDC system, the CCRC chose Rave during a competitive review process of three vendors based on its ability to minimize trial costs and drive studies in any clinical research environment, across global sites and in multiple languages. Rave will also enable its team to further increase collaboration with both Japanese and major international university hospitals throughout Asia, the United States and Europe.

"We look forward to benefitting from Medidata Rave's configurable and user-friendly EDC/CDM system," said Yasuhisa Fujii, assistant professor, CCRC. "Medidata's strong reputation in Japan, particularly for its high-quality product functionality and full support services, was a key factor that influenced our decision to implement Rave."

CCRC plans to complete the Rave implementation by early 2012, leveraging Rave's built-in multi-lingual eLearning training modules to quickly bring its clinical team up to speed. CCRC also plans to participate in the Japan Medidata User Group (J-MUG), a collaborative forum where Medidata customers can share best practices.

"Medidata's established presence and leadership role in the Japanese market has allowed us to successfully serve highly regarded and innovative clinical research institutions such as the CCRC, while also supporting the clinical efforts of the global pharmaceutical industry," said Tarek Sherif, CEO, Medidata Solutions. "Rave will support the CCRC in its ability to increase the number of trials it takes on each year, while also building and strengthening relationships with both pharmaceutical and academic research organizations worldwide."

About Chiba University Hospital Clinical Research Center (CCRC)

Chiba University Hospital, founded in 1874, has a long tradition of excellence in healthcare services with about 500,000 outpatient visits per year, and is also recognized as one of Japan's leading clinical research institutions which have contributed to the development of medical science. The Chiba University Hospital Clinical Research Center (CCRC) was established at Chiba University Hospital in 2000 to facilitate advanced and effective clinical research. The CCRC has been devoted to building the reputation by conducting extensive clinical research with professional expertise and experience, and just in the year 2010, we conducted over 100 clinical trials.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.